European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease
Alongside the FDA’s orphan drug designation in the U.S., the European Commission’s orphan medicinal product designation for mitapivat underscores the urgent need for novel therapies for sickle cell ...
Vandria announces first subjects dosed in its first-in-human Phase 1 clinical trial of VNA-318 brain-penetrant mitophagy inducer
Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today announces that the first subjects have been dosed in its first-in ...
Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure
Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential for consistent revenue growth. See more.
US trade tribunal finds Lenovo smartphones infringe Ericsson patents
The U.S. International Trade Commission said on Tuesday that smartphones made by Lenovo's Motorola Mobility infringe patents ...
JD Supra14h
Sixth Circuit Applies FRE 702 to Class Certification Experts and Highlights Commonality and Predominance Issues for Products That Change Over Time
Class certification decisions under Rule 23 of the Federal Rules of Civil Procedure mark a critical stage in any putative class action lawsuit.
JD Supra15h
Trademark Fee Changes at the USPTO: What You Need to Know
The USPTO will set or adjust numerous trademark fees on January 18, 2025. The USPTO’s summary table of the key changes is available at the end of ...
Flying15h
Purdue Unveils Low-Cost Runway Incursion Prevention Tech
Purdue Polytechnic Institute has unveiled a solar-powered, simplified light system that it says will automatically indicate ...
How Apple Is Losing To Qualcomm In The Great Modem War
The Apple modem fears are overblown, and the company has significant upside catalysts in the future. Click here to read an ...
Sanofi: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most ...